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Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive
inflammation and tissue destruction due to abnormal immune activation. HLH carries
a very highmortality, andwhile delays in patients’ presentation to hospital, time to sus-
picion of HLH, investigation, and initiation of therapy all play a part, mortality remains
high evenwith timely diagnosis and treatment. Classicalmanifestations ofHLH include
persistent fever, cytopenias, and liver dysfunction.
Case presentation:We present four cases of secondary HLH, highlighting the demo-
graphic and clinical characteristics of these patients, underlying triggers (includ-
ing systemic lupus erythematosus, lymphoproliferative disorders, and leishmaniasis),
together with challenges associated with the diagnosis and treatment of this rare dis-
order and a brief review of literature.
Conclusion:HLH has protean manifestations and requires a high index of suspicion as
it can be a great clinical masquerader. Mortality due to multiorgan failure is often high
evenwith early recognition and treatment.
KEYWORDS
hemophagocytic lymphohistiocytosis, HLH-2004 diagnostic criteria, systemic lupus
erythematosus
1 INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of exag-
gerated inflammatory response and tissue destruction due to
abnormal immune activation [1]. It can occur as a familial or spo-
radic disorder, and may be triggered by various immune activating
events.
Primary HLH or familial hemophagocytic lymphohistiocytosis (FHL)
refers to HLH caused by gene mutations and presents in childhood.
Identifiable causes include the following mutations: 9q21.3-22, PRF-1,
UNC 13D, STX 11, and STX BP2, Chediak-Higashi syndrome (CHS-
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1/LYST), Griscelli syndrome type 2 (RAB 27A), Hermansky-Pudlak
syndrome type 2 (AP3B1), and the X-linked lymphoproliferative
syndromes XLP-1 (SAP) and XPL-2 (XIAP) [2].
Secondary (sporadic, acquired) HLH occurs in patients without a
known familial mutation, in some of whom a clear trigger for devel-
opment of HLH can be identified. Acquired or secondary cases of
HLH can be broadly triggered by malignancy, infectious, or autoim-
mune etiology [2–4]. Commonly, these include Epstein-Barr virus
(EBV), cytomegalovirus (CMV), lymphoproliferative disorders and
connective tissue disorders, such as systemic lupus erythematosus
(SLE).
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2 METHODS AND MATERIALS
We conducted a retrospective review of the patient charts of four
patients, who were diagnosed with HLH at the Aga Khan University
Hospital, Nairobi between 2018 and 2019. The diagnosis of HLH was
based on the HLH-2004 guidelines that require five of eight criteria to
qualify for a diagnosis of HLH.
These criteria include fever, cytopenias affecting two lineages
(hemoglobin < 9 g/dL, platelets < 1009/L, neutrophil count < 19/L),
hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis
on biopsy of bone marrow, spleen or lymph node, hyperferritine-
mia>500 ng/mL, impaired natural killer (NK) cell activity, and elevated
CD 25 (soluble interleukin 2 receptor).
3 CASE PRESENTATION AND RESULTS
3.1 Case A
A 30-year-old male patient was referred to our outpatient department
following treatment for neutropenic sepsis and bone marrow failure
at a peripheral facility. He had been unwell for 2 months prior, with
fatigue, unexplained weight loss, and fevers as the predominant symp-
toms. There had been severe anemia necessitating blood transfusion,
easy bruising, and evidence ofmucosal hemorrhage, with gumbleeding
and frank haematuria.
Initial assessment revealed temperature of 39◦C, heart rate (HR)
of 80/minute, respiratory rate (RR) of 20/minute, and blood pressure
(BP) of 90/60mmHg. The physical examinationwas significant for hep-
atosplenomegaly. Initial investigations at timeof admission are summa-
rized in Table 1.
A computerized tomography (CT) scan of the chest and abdomen
revealed features of pulmonary edema, scattered ground glass opaci-
ties, and gross splenomegaly of 20 cm.
Despite broad-spectrum antibiotic therapy, the patient remained
febrile. Blood cultures were unrevealing for any microbial growth.
Aphaeretic platelet transfusions were required, despite which he had
persistent thrombocytopenia. Prothrombin time/international nor-
malized ratio (PT/INR) was within normal limits, making disseminated
intravascular coagulation (DIC) unlikely.
While serum vitamin B12 and serum folic acid levels were nor-
mal, hematinic studies were significant for hyperferritinemia with
ferritin >16 000 ng/mL, immediately raising the suspicion of HLH.
Additional target investigations gave serum triglycerides 5.28 mmol/L
(normal 0.3-1.7), LDH 1807 U/L, and a steep rise of ferritin
75 330 ng/mLwithin 2 days of diagnosis.
According to theHLH-2004 trial, this patient fulfilled the diagnostic
criteria for HLH, with six out of the eight points: fever T> 38.5◦C, bicy-
topenia, splenomegaly on abdominal CT scan, hypertriglyceridemia,
and hyperferritinemia. On theModified 2009 HLH diagnostic score, four
of four clinical criteria (fever, splenomegaly, cytopenias, and hepatitis)
and one of four laboratory criteria (hyperferritinemia) weremet. His H
score was 258 points, assigning a 99.6% probability of having HLH.
TABLE 1 Initial investigations at admission for patient A.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine
aminotransferase; AST, aspartate aminotransferase;
GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase
Initial investigation Value
Reference
range
Hemoglobin 8.6 g/dL 11.5-16.5
MCV 79.60 fL 77-93
MCH 27.40 pg 27-33
Hematocrit 22.2% 37-47
Reticulocyte count 0.11% 0.2-2
Total leucocyte count 0.85× 109/L 4-10
Peripheral blood film Target cells and tear drop
cells. Markedly reduced
platelets. No schistocytes.
Platelet count 4.00× 109/L 150-400
Lactate dehydrogenase 890U/L 135-214
AST 186.60 U/L 0-35
ALT 355.40 U/L 0-35
ALP 171.00 U/L 0-98
GGT 115U/L 0-35
Total bilirubin 43U/L 0-21
Direct bilirubin 31U/L 0-3.4
Albumin 23.5 g/L 35-55
Ferritin 16 731 ng/mL 13-150
Serum potassium 3.55mmol/L 3.3-5.4
Serum creatinine 50Umol/L 58-96
Serum bicarbonate 20.5mmol/L 22-29
Serum sodium 141mmol/L 135-145
Blood urea nitrogen 9.6mmol/L 2.1-7.1
Hepatitis C antibody Negative
Hepatitis B surface antigen Negative
Despite high doses of dexamethasone and etoposide (100mg/mš) as
per theHLH -94 treatment protocol, his conditiondeteriorated further,
withworsening respiratory distress, acute liver failure, andprogressive
confusion. He passed on despite prolonged resuscitative efforts on the
12th day of admission.
By the time the results of the bone marrow trephine biopsy were
available, the patient had passed on. The trephine biopsy revealed a
diagnosis of EBV-positive Classic Hodgkin’s lymphoma, in addition to
CD68 positive scattered histiocytes throughout the bone marrow. In
tandem with this, results of EBV serology nuclear antigen (EBNA) IgG
were received andwere positive at 600 (negative< 5).
3.2 Case B
A 47-year-old woman presented with a 2-week history of general-
ized body weakness. She had been diagnosed with and treated for
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malaria at a peripheral facility. She also had new onset acute kid-
ney injury, which had been attributed to malaria. Initial assessment at
our facility revealed temperature of 38.5◦C, HR 100/min, RR 20/min,
and BP 155/89 mm Hg. Her abdominal examination was significant
for splenomegaly. Initial investigations at presentation are shown in
Table 2.
During the initial workup for anemia, ferritin was noted to be
markedly elevated at 1794 ng/mL, which prompted further workup for
possible inflammatory causes, namely bacterial infection, connective
tissue disease and though lower on the list of possibilities, HLH.
Investigations for an infectious etiology revealed a negative malaria
screen, elevated C-reactive protein (CRP) level 82 mg/L, rising serum
lactate dehydrogenase (LDH) to 2149 U/L, and blood cultures unre-
vealing of anymicrobial growth.
The connective tissue screen revealed a positive antinuclear anti-
body (ANA) in a speckled pattern: titer 1:160, reduced levels of com-
plement C3, while C4 was low normal at 0.11 g/L (normal 0.1-0.4).
Anti-ds-DNA and ENA were negative. Urinalysis revealed proteinuria
of 3+. This gave her a score of 13 on the 2018 SLE criteria from EULAR
(European LeagueAgainst Rheumatism) andACR (AmericanCollege of
Rheumatology). The criteria require that a patient have ANA titer of at
least 1:80 along with 10 points from the clinical and laboratory criteria
for a diagnosis of SLE.
A few days after admission, the ferritin level had risen from 1794
to 6929 ng/mL on admission and there was hypertriglyceridemia of
3.24 mmol/L (normal 0.3-1.7) and falling platelets to a nadir of 103.00
× 109/L.
A CT scan of the chest and abdomen revealed mild hepatomegaly
and splenomegaly of 15 cmwith subcentimeter nodes above andbelow
the diaphragm.
Abonemarrowexaminationperformedon the fifth dayof admission
revealed hypercellular marrow with features of erythroid hyperplasia
and reactive histiocytosis.
According to the HLH-2004 trial, this patient fulfilled the criteria
for a diagnosis of HLH, with five features out of the eight-point diag-
nostic criteria: persistent fever > 38.5◦C, bicytopenia, splenomegaly
on an abdominal CT scan, hypertriglyceridemia, and hyperferritinemia.
Modified 2009HLH diagnostic criteria: four of four clinical criteria (fever,
splenomegaly, cytopenias, and hepatitis), and one of four laboratory
criteria (hyperferritinemia) were met. Her H score was 193 assigning
a probability of 82.9% of having HLH.
A diagnosis of HLH due to SLEwasmade.
Treatment with high doses of steroids was initiated (methylpred-
nisone 500 mg once a day for 3 days), and while she was clinically sta-
ble, laboratory parameters worsened, with rising ferritin from 4433
to 6929 ng/mL and falling platelets and LDH levels from 1520 to
2149 U/L. In view of this, a weekly course of rituximab, which is rec-
ommended in complicated SLE, was initiated, along with tenofovir, for
the chronic hepatitis B infection.
She responded well to this therapy, with resolution of the fever and
reduction of the inflammatory markers. Subsequently, she was started
ondefinitive treatment for SLEwithhydroxychloroquineandmycophe-
nolatemofetil, and continues todowell on this therapy10months later.
TABLE 2 Initial Lab investigations for Patient B
Initial
investigation Value
Reference
range
Hemoglobin 7.8 g/dL 11.5-16.5
MCV 79.4 fL 77-93
MCH 29.2 pg 27-33
Hematocrit 13.7% 37-47
Reticulocyte
count
4.49% 0.2-2
Total leucocyte
count
9.7× 109/L 4-10
Platelet count 326.00× 109/L 150-450
Peripheral blood
film
Mild auto agglutinationwith
target cells, basophilic
stippling of RBC and left
shift of granulocytes.
Adequate platelets.
Lactate
dehydrogenase
994U/L 135-214
AST 43.6 U/L 0-35
ALT 16.3 U/L 0-35
ALP 182U/L 0-98
GGT 164U/L 0-35
Total bilirubin 28.9 U/L 0-21
Direct bilirubin 12.9 U/L 0-3.4
Albumin 26.1 g/L 35-55
Malaria antigen Negative
Malaria parasite Absent
Direct Coomb’s
test
Negative
Ferritin 1794 ng/mL 13-150
Folate 10.75 ng/mL Deficient< 3
Vitamin B12 624.7 pg/mL 191-663
Serum iron 8.52 Umol/L 6.6-26
Serum potassium 5.02mmol/L 3.3-5.4
Serum creatinine 141Umol/L 58-96
Serum
bicarbonate
19.1mmol/L 22-29
Serum sodium 128mmol/L 135-145
Blood urea
nitrogen
7mmol/L 2.1-7.1
Hepatitis B
surface antigen
Positive
Hepatitis C
antibody
Negative
Hepatitis B viral
load
817 IU/mL
Hepatitis B
E-antigen
Negative
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TABLE 3 Initial Lab investigations for Patient C
Initial
investigation Value
Reference
range
Hemoglobin 10.8 g/dL 11.5-16.5
MCV 78 fL 77-93
MCH 27pg 27-33
Hematocrit 31.4% 37-47
Reticulocyte
count
2.37% 0.2-2
Total leucocyte
count
1.49× 109/L 4-10
Platelet count 5 .00× 109/L
Peripheral blood
film
Mild anisopoikilocytosis,
marked leukopenia and
markedly reduced
platelets. No schistocytes
Lactate
dehydrogenase
1140U/L 135-214
Fibrinogen 1.1 g/L 2-4
AST 299.4 U/L 0-35
ALT 38U/L 0-35
ALP 346U/L 0-98
GGT 213U/L 0-35
Total bilirubin 20.6 U/L 0-21
Direct bilirubin 15.5 U/L 0-3.4
Albumin 22.2G/L 35-55
Malaria antigen Absent
Malaria parasite Absent
Ferritin 66567 ng/mL 13-150
Serum iron 14.8 Umol/L 6.6-26
Serum potassium 4.61mmol/L 3.3-5.4
Serum creatinine 79Umol/L 58-96
Serum
bicarbonate
22.6mmol/L 22-29
Serum sodium 131mmol/L 135-145
Blood urea
nitrogen
9.5mmol/L 2.1-7.1
Hepatitis B
surface antigen
Negative
Hepatitis C
antibody
Negative
HIV Negative
3.3 Case C
A 25-year-old male presented with a 4-week history of weight loss,
fevers, fatigue, diarrhea, vomiting, and abdominal pain. He had been
treated at a peripheral facility with artemether lumefantrine for sus-
pectedmalaria, and also received broad-spectrumantibiotics (ceftriax-
one and doxycycline).
F IGURE 1 Leishmania donovani bodies in bonemarrow aspirate
In our emergency room, he was found to be pale and had scleral
icterus. Initial assessment revealed temperature 38.7◦C, HR 87/min,
RR 20/min, and BP 90/58mmHg. Apart from hepatosplenomegaly, the
rest of the physical examination was unremarkable. Initial investiga-
tions at the time of the presentation are shown in Table 3.
He received fluid resuscitation andwas admitted to the high depen-
dency unit (HDU) with a working diagnosis of septic shock and treat-
ment commenced with broad-spectrum antibiotics. A bone marrow
biopsy performed on the first day of admission for severe pancytope-
nia revealed extracellular and intracellular Leishmania donovani bod-
ies, increased histiocytic activity, and evidence of hemophagocytosis
(Figures 1 and 2).
His H scorewas 303 points assigning a 99.97% probability of having
HLH. According to theHLH-2004 trial, this patient fulfilled the diagno-
sis, with six features out of the eight-point diagnostic criteria for HLH:
persistent fever > 38.5◦C, pancytopenia, splenomegaly, hypertriglyc-
eridemia of 5.22 mmol/L, hyperferritinemia, and increased histiocytic
activity onabonemarrowaspirate, onwhich therewas also evidenceof
L. donovani bodies, clinching the overall diagnosis; HLH was secondary
to visceral leishmaniasis.
He was started on liposomal amphotericin B for 10 days along-
side pulsed methylprednisone at 250 mg daily for 4 days, despite
which he developed worsening respiratory distress that progressed
to ARDS, requiring intubation and mechanical ventilation. He devel-
oped DIC, and blood stained endotracheal aspirates, which coupled
with increasing ventilator requirements, were suggestive of alveolar
hemorrhage.
His stay in the ICU was complicated by multiorgan dysfunction sec-
ondary to Klebsiella pneumoniae and coagulase negative staphylococ-
cal septicemia, acute kidney injury, and refractory DIC, which failed to
respond to aggressive treatment, leading to his demise 15 days after
admission.
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F IGURE 2 Hemophagocytosis of erythrocytes inside the
macrophage
3.4 Case D
A 27-year-old patient presented with fever and chills, headaches,
shortness of breath on exertion, nausea, and joint pains of 2 days dura-
tion. She had been treated for presumed malaria a week prior to her
presentation to us.
Clinical examination at admission was significant for temperature
38◦C, dark macular patches over the abdominal wall and limbs, the
latter of which had been present for about 10 months, and hepato-
splenomegaly. Initial laboratory investigations at the time of the pre-
sentation are shown in Table 4.
She gave a history of having sought medical attention for joint pains
a year previously, but had not received specific treatment for this sus-
pected arthritis. At the time, she hadmild anemia (hemoglobin 10 g/dL),
for which iron supplementation had been recommended.
Investigation of the severe anemia revealed a positive direct
Coomb’s test and an elevated LDH 1660 IU, initially suggestive of
hemolysis. However, the hematinic screen gavemarked hyperferritine-
mia, of >50000 ng/mL, which was alarming and prompted a diagnos-
tic workup for HLH. This gave serum fibrinogen level 3.04 g/L, and
serum triglyceride level of 3.88 mmol/L, while serum LDH rose to
3965U/L.
Due to fever, elevatedCRP72mg/mL, and procalcitonin 10.5 ng/mL,
broad-spectrum antibiotics were initiated. The quantitative buffy coat
test for malaria was positive and so she was initially managed for
malaria, with intravenous artesunate. However, both thick and thin
films were subsequently negative for malaria parasite within 24 h of
admission, as was themalaria antigen test. This, and the fact that there
was no history of travel to a malaria endemic area, made the diagnosis
of malaria unlikely.
TABLE 4 Initial laboratory investigations for patient D
Initial investigation Value
Reference
range
Hemoglobin 4.2 g/dL 11.5-16.5
MCV 75 fL 77-93
MCH 25 pg 27-33
Hematocrit 13.7% 37-47
Reticulocyte count 11.54% 0.2-2
Total leucocyte count 18.58× 109/L
(neutrophilia, bicytopenia,
and no schistocytes)
4-10
Platelet count 65.00× 109/L
Peripheral blood film Mild autoagglutination,
anisopoikilocytosis,
spherocytes, and reduced
platelets.
Lactate
dehydrogenase
1669U/L 135-214
Fibrinogen 3.04 g/L 2-4
AST 146.60 U/L 0-35
ALT 19.1 U/L 0-35
ALP 54U/L 0-98
GGT 30U/L 0-35
Total bilirubin 14.1 U/L 0-21
Direct bilirubin 5.3 U/L 0-3.4
Albumin 33.7 g/L 35-55
Malaria antigen Positive
Malaria parasite Absent
Direct Coomb’s test Positive
Ferritin 54 396 ng/mL 13-150
Folate >20 ng /mL Deficient< 3
Vitamin B12 376 pg/mL 191-663
Serum iron 14.8 Umol/L 6.6-26
Serum potassium 4.47mmol/L 3.3-5.4
Serum creatinine 86Umol/L 58-96
Serum bicarbonate 15mmol/L 22-29
Serum sodium 128mmol/L 135-145
Blood urea nitrogen 7mmol/L 2.1-7.1
Blood cultures assessed after 5 days were unrevealing for any
microbial growth. Bone marrow biopsy was performed on the fourth
day of admission, which showed increased hemophagocytic activity
corroborated by an increase in CD68 positive histiocytes. Given the
longstanding joint pains and skin lesions, an autoimmune screen was
requested.
According to the HLH-2004 trial, this patient fulfilled the diagno-
sis, with six features out of the eight-point diagnostic criteria for HLH,
including a persistent fever >38◦C, bicytopenia, splenomegaly, hyper-
triglyceridemia, hyperferritinemia, and a histiocytic activity on a bone
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TABLE 5 This table provides the demographic and clinical characteristics of the four patients at the time of diagnosis with HLH
CASE A B C D
Gender Male Female Male Female
Time of onset of symptoms to
referral
2months 2weeks 4weeks 1week
Age at diagnosis 30 47 25 27
Fevers Yes Yes Yes Yes
Splenomegaly Yes Yes Yes Yes
Cytopenias Pancytopenia Bicytopenia Pancytopenia Pancytopenia
Ferritin> 500 ng/mL 16 731 1794 66 567 54 396
Triglyceridemia> 3mmol/L 5.28 3.24 3.78 3.88
Transaminitis Yes yes Yes Yes
Hemophagocytosis on bonemarrow Yes No Yes with Leishmania
donovani bodies
Yes
HLH 2004 sore 6 5 6 6
H score 258 193 303 243
Associated Infections/malignancy/
autoimmune condition
Classic Hodgkin’s
lymphoma
SLE Leishmaniasis SLE
Type of therapy Etoposide and
dexamethasone
Methylprednisone and
rituximab
Amphotericin B and
methylprednisone
Methylprednisone
Outcome Dead Alive Dead Dead
Abbreviation: HLH, hemophagocytic lymphohistiocytosis; SLE, systemic lupus erythematosus.
marrow aspirate. Her H scorewas 243 points assigning a 99.1% proba-
bility of having HLH.
Shewas clinically stable, reporting that she felt better within 48 h of
admission. However, transient confusion was noted, overnight, which
had settled by the followingmorning.
Four days into her admission, and after the first dose ofmethylpred-
nisolone and red cell transfusion, she suffered a tonic clonic seizure,
suffered a cardiac arrest, and died despite prolonged resuscitation
attempt.
Results of the autoimmune screen were obtained 1 day later, and
gave positive ANA in a speckled pattern, negative double-stranded
DNA (dsDNA), while the extractable nuclear antigen was positive for
both anti-Sm and anti-RNP, clinching the diagnosis in this case to be
HLH in a patient with untreated SLE.
Transient confusion while on the ward coupled with a seizure prior
to death are highly suggestive of CNS HLH, which carries a dire prog-
nosis.
4 SUMMARY OF RESULTS
The age of the patients ranged from 25 to 47 years (male to female
ratio 1:1). Fever of undetermined origin, cytopenias, hyperferritine-
mia, and either splenomegaly or hepatosplenomegaly were prominent
features at presentation in each of the cases. All patients met the
modified HLH diagnostic criteria according to the HLH-2004 guide-
lines that require five out of eight criteria to qualify for a diagnosis
of HLH. The clinical and laboratory characteristics are summarized in
Table 5.
All patients had deranged liver transaminases at presentation with
elevated AST levels. Three patients had hemophagocytosis on bone
marrow, while the fourth had an increase in the number of histi-
ocytes. Leishmania donovani bodies were present in the bone mar-
row of one patient alongside the hemophagocytosis. Soluble IL 2
and NK cell testing are not available in our country hence were not
tested.
A secondary cause of the HLH was identified in all of the patients;
two had previously undiagnosed and untreated SLE, one visceral leish-
maniasis and the fourth classic EBV-driven Hodgkin’s lymphoma.
5 DISCUSSION
HLH is a syndrome of excessive inflammation and tissue destruc-
tion due to abnormal immune activation. HLH is on the spectrum
of macrophage activating syndromes, in which over activation of
macrophages leads not only to exaggerated cytokine production, but
also to hyperferritinemia, in the release of iron frommacrophages, and
hemophagocytosis of blood cells [5–8].
The sustained activation of macrophages, NK cells, and cytotoxic
T cells leads to excessive cytokine production. The persistent produc-
tion of cytokines, including interferon gamma, tumor necrosis factor
alpha, interleukins (ILs) such as IL-6, IL-10, and IL-12, and the soluble
IL-2 receptor, further recruits additional inflammatory cells, in a vicious
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cycle, leading to a cytokine storm. This cytokine storm is the primary
mediator of tissue damage [9].
Macrophages are a storage reservoir of ferritin, and this accounts
for high ferritin levels inHLH [10]. Recordedpeak ferritin levels greater
than 10 000 g/L was found to have a 90% sensitivity and 96% speci-
ficity forHLHduring a study done at the Texas Children’s Hospital [11].
Therefore, when the clinical and laboratory features are suggestive, a
serum ferritin of>10 000 g/L strongly supports a diagnosis of HLH [2].
This was certainly reflected in three of four cases of this series, where
ferritin, initially performed in assessmentof anemia, unexpectedly gave
hyperferritinemia > 10 000 g/L, immediately triggering investigations
for HLH.
The most common presentation of HLH as per the HLH-2004
study included fever, splenomegaly, bicytopenia, hypertriglyceridemia
or hypofibrinogenemia, hemophagocytosis, ferritin > 500 mcg/L, low
or absent NK cell activity, and soluble CD25 elevation [12]. As sum-
marized above, all four patients described in this series presented with
fever, splenomegaly, hyperferritinemia, and cytopenias.
In the early stages of HLH, hemophagocytosis might not be seen
in the bone marrow. This and the patchy nature of this phenomenon
in bone marrow samples mean that its absence does not negate HLH
as the diagnosis. The incidence of bone marrow involvement varies
between 25% and 100% [13] and bone marrow analysis for presence
of hemophagocytosis has a sensitivity of around 60% [14]. One of the
patients (Case B) did not have hemophagocytosis on the bone mar-
row, but did have an excess of histiocytes within the bonemarrow. This
probably corresponds with the patient having the "mildest" and possi-
bly earliest form of HLH in the cohort and hence being picked up at the
earlier than the other cases.
The overall mortality of HLH is high, varying between 26.5 and
74.8%, and depends on the patient characteristics, underlying precip-
itating conditions, and stage of disease [15]. This was also seen in our
case series, which reported a highmortality rate, with the only survivor
having been diagnosed at a relatively early stage of the disease course,
and remaining in good health to date.
5.1 Diagnostic criteria
The diagnostic criteria is based on theHLH-2004 trial [12,16]. Tomake
a diagnosis, at least five out of eight findings are required as high-
lighted in Tables 6 and 7. All the patients in this case series (100%)
fulfilled both the 2004 and the modified 2009 HLH criteria. Addition-
ally, the HLH H score was calculated for each patient and gave a high
probability of HLH in all the patients (99% for cases A, C, D, and for
82.9% for case B). The H score is a weighted criteria score, validated
for diagnosis in secondary adult causes of HLH. It is aimed at achiev-
ing a more effective estimate of the probability of HLH and consists of
graded clinical and laboratory parameters with a sensitivity and speci-
ficity of 90% and 79% [17]. In a retrospective study done to com-
pare the performance of HLH-2004 guidelines with the new H-score,
H-score performed better in identifying HLH at presentation among
adult patients [15,18,19].
TABLE 6 HLH diagnostic criteria; at least five of eight findings
present
1. Fever≥38.5◦C
2. Splenomegaly
3. Ferritin> 500 ng/mL
4. Peripheral blood cytopenias, with at least two of the
following: hemoglobin< 9 g/dL; platelets< 100.00×
109/L; absolute neutrophil count< 1× 109/L
5. Hypertriglyceridemia (fasting triglycerides> 3mmol/L)
and/or hypofibrinogenemia (fibrinogen< 150mg/dL)
6. Hemophagocytosis in bonemarrow, spleen, lymph
node, or liver
7. Low or absent natural killer (NK) cell activity
8. Elevated soluble CD25 (soluble IL-2 receptor alpha
[sIL-2R]) two standard deviations above
age-adjusted laboratory-specific norms
TABLE 7 Modified 2009HLH criteria
Clinical Three of four clinical findings 1. Fever
2. Splenomegaly
3. Cytopenias
4. Hepatitis
Plus
Immune
markers
One of four immunemarkers 1. Hemophagocytosis
2. Increased ferritin
3. Hypofibrinogenemia
4. Absent or very decreased
NK cell function
5.2 Triggers of HLH
In all four cases, a trigger for HLH was identified, but in only one of
these cases, characterised by early patient presentation, timely clini-
cal suspicion, work up and treatment resulted in a favourable patient
outcome. Macrophage activation has been reported to be triggered
by infections, most commonly viral infections such as EBV [20–22],
and has also been associated with leishmaniasis and CMV [22]. Malig-
nancies, most commonly lymphoproliferative, are also recognized to
be activators of the immune system as are autoimmune conditions.
Although a seemingly heterogeneous group of conditions, the disor-
ders mentioned above all have the ability to activate the immune sys-
tem and lead to a macrophage activating syndrome typical of HLH,
characteristic of the disordered, exaggerated response, and its resul-
tant tissue damage.
5.3 Treatment
Therapy is based on the HLH-94 protocol [23,24]. The standard treat-
ment is corticosteroids, to which etoposide is added in cases which
do not initially respond, and in which no other cause is found for
the HLH, along with identification and treatment of any underlying
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cause. Rituximab is recommended in EBV-driven HLH, with the mech-
anism of action being eradication of the EBV reservoir through clear-
ance of B cells [15,19]. For central nervous system disease, intrathecal
methotrexate and hydrocortisone are added to the induction therapy
[24]. In patients not showing signs of improvement, the above therapy
is continuedwhile planning for allogeneic hematopoietic cell transplan-
tation in suitable cases.
Patient A had EBV-driven classical Hodgkin’s lymphoma but the
diagnosis was only available postmortem. Additionally, he had been
unwell for a number of months prior to presentation. Despite initiating
etoposide and methylprednisolone within days of presentation at our
center, he had a rapid clinical deterioration and died. Rituximab ther-
apywould have been a recommendation in his case, had EBVPCRbeen
performedand foundpositive [15,19].HLHassociatedwith lymphomas
tends to have a higher mortality compared to HLH due to infections
and autoimmune conditions [22]. Worsening cytopenias and cholesta-
sis are predictive of death in HLH, and a rapid drop in ferritin levels
after initiation of treatment is associated with improved outcome [25].
Both patients B and D had SLE. However, while patient B had a his-
tory of symptoms that had been present for approximately 1 month,
patientDhad symptoms formore than10months, and indeedhadbeen
evaluated and found to have joint pains, anemia, and skin lesions at that
time, but had been lost to follow up. Both patients had ferritin assess-
ment early on as part of the investigation of the cause of anemia at pre-
sentation. Patient B’s ferritin level was 1794 ng/mL, while patient D’s
ferretin level was 54 396 ng/mL.
A high index of suspicion of HLH in patient B, mainly because there
were no other significant pointers to an alternative pathology led to
early initiation of high-dosemethylprednisolone, and subsequent posi-
tive ANA serology allowed for definitive treatment of SLE. This patient
responded well to treatment and is now asymptomatic, more than a
year later.
Although patient D’s elevated ferritin was also investigated
promptly, hyperferritinemia > 50 000 at presentation is indicative
of already established macrophage activation, which could not be
reversed even with timely treatment. Additionally, the fact that she
had transient neurological symptoms and a generalized seizure is
highly suggestive of neuro-HLH, which carries a grave prognosis.
Patient C had a bone marrow diagnosis of leishmaniasis, coupled
with features of advanced HLH. However, he too presented several
weeks after falling ill, and receiving antibiotic therapy for presumed
bacterial infection at another center. Despite high dose of methylpred-
nisolone and amphotericin B, it was impossible to reverse the estab-
lishedHLHandmultiorgan failure, whichwere present at presentation,
leading to his adverse outcome.
6 CONCLUSION
Diagnosis of HLH presents a diagnostic challenge to clinicians due to
the nonspecific signs and symptoms that portend awide array of differ-
ential diagnosis. Therefore, a high index of suspicion iswarranted espe-
cially when a patient presents with unremitting fevers and cytopenias.
In our series, an unexpectedly high ferritin, which in each casewas per-
formed early in course of admission to investigate anemia, resulted in
early suspicion of the condition and relatively early appropriate inves-
tigations and treatment for HLH.
However, despite benefitting from an early diagnosis and initiation
of therapy for HLH, vis-a-vis their admission to our facility, three of
these patients presented with already established macrophage activa-
tion, HLH, and features of organ failure. Therefore, the HLH-directed
treatment, though appropriate, proved futile in these cases.
The mortality of patients with HLH is very high and delay in diagno-
sis confers the greatest risk to a fatal outcome, as shown in this series
where the time to presentation ranged from 2weeks to 2months.
This case series highlights the difficulty in obtaining a good outcome
in HLH, even when the diagnosis is suspected early on. Additionally,
HLH was not suspected at peripheral facilities, probably due to a com-
bination of factors: (a) it is uncommon and shares features with sepsis,
which is far more common; (b) ferritin level, which was markedly ele-
vated and prompted a search for HLH at our center, is not widely avail-
able at peripheral facilities and can be costly.
It cannot be stressed enough that a high index of suspicion is war-
ranted, when faced with a patient with a triad of fever, cytopenias, and
organomegaly, which is unexplained, and that checking a ferritin level
in this case may highlight unexplained hyperferritinemia and lead to
appropriate investigations for HLH. The patients described here were
diagnosed with HLH promptly within our service, partly because we
were able to quickly discount alternative diagnoses as treatment of
these had already been initiatedwith poor outcome at peripheral facil-
ities.
A multidisciplinary approach, including early consultations with a
haematologist, either remotely or in person is essential to promptly
investigate and initiate appropriate therapy, which is relatively acces-
sible. Prompt, lifesaving and timely treatment, is likely to have to be
initiated before all test results have been returned, hence relying on a
consensus of clinical and laboratory features compatible with the diag-
nosis, but not yet diagnostic of it.
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